The global market for mRNA Therapeutics Contract Development & Manufacturing Organization was estimated at US$5.0 Billion in 2024 and is projected to reach US$9.0 Billion by 2030, growing at a CAGR of 10.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the mRNA Therapeutics Contract Development & Manufacturing Organization market.
Segments: Indication (Infectious Diseases Indication, Metabolic & Genetic Diseases Indication, Cardiovascular & Cerebrovascular Diseases Indication); Application (Viral Vaccines Application, Protein Replacement Therapies Application, Cancer Immunotherapies Application); End-Use (Biotech Companies End-Use, Government & Academic Research Institutes End-Use, Pharmaceutical Companies End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global mRNA Therapeutics Contract Development & Manufacturing Organization Market - Key Trends & Drivers Summarized
Why Is the Demand for mRNA Therapeutics CDMOs Increasing?
The rise of mRNA-based drugs and vaccines has dramatically increased the demand for contract development and manufacturing organizations (CDMOs) specializing in mRNA therapeutics. As biotechnology and pharmaceutical companies focus on research and development, many lack the infrastructure required for large-scale mRNA production, driving the need for specialized CDMOs. These organizations provide essential services, including raw material sourcing, in vitro transcription (IVT), purification, and lipid nanoparticle (LNP) formulation. The rapid scalability of mRNA therapeutics, particularly demonstrated during the COVID-19 pandemic, has reinforced the importance of CDMOs in ensuring global vaccine and drug supply. Additionally, the expansion of mRNA applications beyond vaccines into personalized medicine, cancer immunotherapy, and rare disease treatments has increased the complexity of production, making outsourcing to expert CDMOs a strategic necessity. As the biotech industry continues to innovate, CDMOs have become crucial in bridging the gap between clinical development and commercial manufacturing, ensuring that mRNA therapeutics reach the market efficiently and cost-effectively.What Innovations Are Transforming the Manufacturing of mRNA Therapeutics?
Technological advancements have significantly improved the efficiency and scalability of mRNA therapeutics manufacturing, enhancing the role of CDMOs in drug production. One of the most critical innovations is the development of automated and closed-system IVT processes, which reduce contamination risks and improve batch consistency. The refinement of lipid nanoparticle (LNP) encapsulation technology has also improved mRNA stability and targeted delivery, ensuring optimal therapeutic effects. AI-driven optimization of mRNA sequence design and predictive modeling have enabled CDMOs to refine production parameters, reducing waste and improving yield. Additionally, advancements in single-use bioprocessing systems have allowed CDMOs to enhance flexibility while minimizing costs and cross-contamination risks. Continuous manufacturing and real-time quality control systems have further streamlined production workflows, enabling faster turnaround times for clinical and commercial-scale manufacturing. As mRNA-based therapies evolve to include self-amplifying RNA (saRNA) and circular RNA (circRNA), CDMOs are investing in cutting-edge production techniques to meet the growing demand for innovative mRNA platforms.How Are Regulatory and Supply Chain Factors Shaping the CDMO Market for mRNA Therapeutics?
The increasing complexity of regulatory requirements and global supply chain dynamics is shaping the operational strategies of mRNA-focused CDMOs. Regulatory agencies such as the FDA and EMA have established stringent guidelines for mRNA therapeutics, requiring CDMOs to maintain GMP-compliant facilities and implement rigorous quality control protocols. The evolving landscape of personalized medicine has further complicated regulatory approval pathways, particularly for mRNA-based cancer vaccines and gene therapies that require customized formulations. The global supply chain for essential raw materials, including nucleotides, capping reagents, and lipids, has also faced disruptions, prompting CDMOs to invest in regional manufacturing hubs and vertical integration strategies to ensure uninterrupted production. Additionally, collaborations between CDMOs and biotech firms have strengthened supply chain resilience, enabling rapid response to emerging healthcare challenges. The adoption of digital manufacturing platforms and blockchain-based tracking systems has further improved traceability and compliance, ensuring transparency in the production and distribution of mRNA-based drugs.What Are the Key Growth Drivers in the mRNA Therapeutics CDMO Market?
The growth in the mRNA therapeutics CDMO market is driven by several factors, including the increasing investment in mRNA drug development, expanding biopharmaceutical pipelines, and the rising need for scalable manufacturing solutions. The success of mRNA-based COVID-19 vaccines has accelerated funding for next-generation mRNA therapies, leading to a surge in clinical trials for infectious diseases, oncology, and metabolic disorders. Pharmaceutical companies are increasingly outsourcing mRNA production to CDMOs to reduce operational costs and accelerate time-to-market. The emergence of next-generation RNA technologies, such as self-amplifying RNA and circular RNA, has further increased demand for specialized CDMO capabilities. Additionally, the growing adoption of modular and single-use bioprocessing systems has enabled CDMOs to offer flexible, cost-effective manufacturing solutions. As governments and biotech firms prioritize pandemic preparedness and personalized medicine, the role of mRNA therapeutics CDMOs is expected to expand, ensuring that innovative mRNA-based treatments reach global markets efficiently and at scale.Report Scope
The report analyzes the mRNA Therapeutics Contract Development & Manufacturing Organization market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Indication (Infectious Diseases Indication, Metabolic & Genetic Diseases Indication, Cardiovascular & Cerebrovascular Diseases Indication); Application (Viral Vaccines Application, Protein Replacement Therapies Application, Cancer Immunotherapies Application); End-Use (Biotech Companies End-Use, Government & Academic Research Institutes End-Use, Pharmaceutical Companies End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Infectious Diseases Indication segment, which is expected to reach US$5.0 Billion by 2030 with a CAGR of a 8.8%. The Metabolic & Genetic Diseases Indication segment is also set to grow at 12.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $1.3 Billion in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $1.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global mRNA Therapeutics Contract Development & Manufacturing Organization Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global mRNA Therapeutics Contract Development & Manufacturing Organization Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AGC Biologics, Aldevron, ARCALIS, Inc., BioNTech SE, Catalent, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 34 Featured):
- AGC Biologics
- Aldevron
- ARCALIS, Inc.
- BioNTech SE
- Catalent, Inc.
- CordenPharma International
- Curia Global, Inc.
- FUJIFILM Diosynth Biotechnologies
- Laboratorios Farmacéuticos Rovi, S.A.
- Lonza Group
- Merck KGaA
- Moderna, Inc.
- Rentschler Biopharma SE
- Samsung Biologics
- ST Pharm
- Thermo Fisher Scientific
- TriLink BioTechnologies
- Vernal Biosciences
- WuXi AppTec
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AGC Biologics
- Aldevron
- ARCALIS, Inc.
- BioNTech SE
- Catalent, Inc.
- CordenPharma International
- Curia Global, Inc.
- FUJIFILM Diosynth Biotechnologies
- Laboratorios Farmacéuticos Rovi, S.A.
- Lonza Group
- Merck KGaA
- Moderna, Inc.
- Rentschler Biopharma SE
- Samsung Biologics
- ST Pharm
- Thermo Fisher Scientific
- TriLink BioTechnologies
- Vernal Biosciences
- WuXi AppTec
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 166 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5 Billion |
| Forecasted Market Value ( USD | $ 9 Billion |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
